# Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

> **NCT05429372** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 10 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **GENETIC:** PF-06939926

## Key facts

- **NCT ID:** NCT05429372
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-08
- **Primary completion:** 2025-10-03
- **Final completion:** 2025-10-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in one combined study: C3391003
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429372, "Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05429372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*